retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 is a triple-agonist drug targeting GLP-1, GIP, and receptors to suppress appetite and boost thermogenesis. trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing Structural insights into the triple
Description
Both medications are available in the same dose, form, and route of administration
Diabetes and obesity, while primary cardiometabolic diseases, have significant negative effects on muscles, tendons and joints
GLP-1R Activation At the GLP-1 receptor, retatrutide stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release from pancreatic alpha cells, and reduces gastric emptying rate
This article covers what the research actually says about both
Electronically published ahead of print (DOI: 10.1056/NEJMoa1603827) [DOI] [PMC free article] [PubMed] [Google Scholar] 33.Marso SP, Bain SC, Consoli A, et al
Die Folge ist, dass dadurch weniger Na + sich im weiterfhrenden System der Tubuli befindet
